Calamos Advisors LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 145,688 shares of the medical research company’s stock after selling 43,019 shares during the period. Calamos Advisors LLC’s holdings in IQVIA were worth $24,846,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in IQVIA by 43.8% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,677 shares of the medical research company’s stock valued at $457,000 after buying an additional 815 shares during the period. Principal Financial Group Inc. lifted its position in IQVIA by 3.6% in the first quarter. Principal Financial Group Inc. now owns 196,198 shares of the medical research company’s stock valued at $33,460,000 after buying an additional 6,897 shares during the last quarter. First Growth Capital LLC boosted its stake in IQVIA by 3.2% during the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares during the period. Chicago Partners Investment Group LLC increased its position in shares of IQVIA by 1.5% during the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 70 shares during the last quarter. Finally, Applied Finance Capital Management LLC increased its position in shares of IQVIA by 11.4% during the first quarter. Applied Finance Capital Management LLC now owns 3,635 shares of the medical research company’s stock valued at $620,000 after acquiring an additional 373 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on IQV. Robert W. Baird upped their price objective on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $225.71.
IQVIA Trading Up 0.2%
Shares of IQV stock opened at $208.00 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a 50 day moving average price of $183.23 and a 200 day moving average price of $188.27. The stock has a market capitalization of $34.72 billion, a P/E ratio of 25.78, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the business earned $2.70 EPS. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.
IQVIA declared that its board has initiated a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
